Translational Research Develops Intranasal Formulation of Granisetron, Antiemetic Agent.Tokyo, Japan, May 26, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Translational Research, a subsidiary of Shin Nippon Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Laboratories, has developed an intranasal in·tra·na·sal adj. Within the nose. formulation of granisetron, an agent with antiemetic efficacy. Granisetron is commonly used in reducing side effects of antitumor an·ti·tu·mor also an·ti·tu·mor·al adj. Counteracting or preventing the formation of malignant tumors; anticancer. Adj. 1. therapy. In experiments on monkeys, the company confirmed that the new formulation has an immediate action equivalent to injections as well as excels in absorbability through nasal mucosa. The company expects that the new formulation may help improving the quality of life of cancer patients suffering from side effects. Going forward, the company plans to begin phase I clinical trials with a view to commercializing it around 2010. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion